Resistant Hypertension Clinical Trial
— TRYCORTOfficial title:
Treatment of Resistant Hypertension: Cohort Study
NCT number | NCT05087940 |
Other study ID # | TRYCORT 1.1 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2021 |
Est. completion date | December 31, 2022 |
Verified date | February 2023 |
Source | Galenika AD Beograd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a multicenter, prospective observational cohort study. It will compare effectiveness and safety of various add-on treatment options in regard to arterial blood pressure control in adult patients with treatment resistant hypertension: an aldosterone receptor blocker (e.g. spironolactone), a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker. The add-on therapy will be prescribed to the patients within the scope of their routine medical care, independently from the study investigators. The patients will be followed up for 6 months, with monthly visits and continuous home blood pressure diary kept by the patients themselves.
Status | Completed |
Enrollment | 731 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Resistant hypertension is defined as casual blood pressure during clinical examination of more than 140/90 mmHg despite treatment with optimal or best-tolerated doses of three or more drugs, which should include a diuretic, typically an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), and a calcium channel blocker (CCB) (or beta blocker). All reference blood pressures will be taken as a mean of the 2nd and 3rd measurements in physician's office during a single examination, measured at least 3 min apart 3. Aged 18 years or above 4. Inadequate control of hypertension is confirmed with home blood pressure monitoring (average of morning and evening measurements after 5 minutes of relaxation in sitting position, for 6 days) Exclusion Criteria: 1. Pregnancy, anticipated pregnancy, or breastfeeding 2. Incarceration or institutionalized living which may prohibit measurement of home blood pressure 3. Participation in another intervention study that may affect blood pressure 4. Patients in whom systolic blood pressure is not measurable (e.g. those with left ventricular assist devices) 5. Hypotension: average systolic blood pressure <100 mmHg over last 2 weeks prior to screening while not taking any blood pressure medications 6. Life expectancy <4 months 7. Anticipated living donor kidney transplant within 4 months 8. Patients with a systolic blood pressure value over 220 mmHg requiring immediate adjustments of therapy 9. Patients with moderate to severe renal insufficiency (acute or chronic) with glomerular filtration rate of less than 30 ml/min 10. Patients with active bronchospastic disorders 11. Heart failure classes III and IV 12. Severe bradycardia (heart rate below 50/min), 2nd and 3rd degree AV block 13. Patients with a history of hypersensitivity to any of the drugs under study 14. Patients already using add-on therapy |
Country | Name | City | State |
---|---|---|---|
Serbia | Clinical Center of Serbia | Belgrade | |
Serbia | Clinical Hospital Center Zemun | Belgrade | |
Serbia | Clinical Hospital Center Zvezdara | Belgrade | |
Serbia | Medical Military Academy | Belgrade | |
Serbia | University Clinical Hospital Center Dragisa Misovic - site 1 | Belgrade | |
Serbia | University Clinical Hospital Center Dragisa Misovic - site 2 | Belgrade | |
Serbia | University Hospital Medical Center Bezanijska Kosa | Belgrade | |
Serbia | University Clinical Center Kragujevac | Kragujevac | |
Serbia | General Hospital Leskovac | Leskovac | |
Serbia | Clinical Center Nis | Niš | |
Serbia | Institute of Cardiovascular Diseases of Vojvodina | Sremska Kamenica | |
Serbia | General Hospital Subotica | Subotica |
Lead Sponsor | Collaborator |
---|---|
Galenika AD Beograd | Medicinsko društvo za racionalnu terapiju Republike Srbije (MEDRAT) |
Serbia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of normalization of arterial blood pressure | Decrease of arterial blood pressure to normal levels according to the 2018 European Society for Cardiology (ESC)/European Society for Hypertension (ESH) Guidelines (<140/90 mmHg) after 1,2,3,4,5 and 6 months | 6 months | |
Primary | Rate of reduction of systolic arterial blood pressure | Reduction of systolic arterial blood pressure for 10 mmHg or more after 1,2,3,4,5 and 6 months | 6 months | |
Primary | Rate of reduction of diastolic arterial blood pressure | Reduction of diastolic arterial blood pressure for 5 mmHg or more after 1,2,3,4,5 and 6 months | 6 months | |
Primary | Adverse events rate | Incidence of adverse events | 6 months | |
Primary | Treatment withdrawal rate | Tolerability | 6 months | |
Secondary | Blood pressure | Absolute value of arterial blood pressure at scheduled study visits | 6 months | |
Secondary | Renal function | Parameters of renal function - serum level of creatinine and absolute value of proteinuria | 6 months | |
Secondary | Quality of life on a scale 0 to 1 | Quality of life at a visual analogue scale | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05545059 -
Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT04388124 -
VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
|
Phase 2 | |
Withdrawn |
NCT01939392 -
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
|
Phase 2/Phase 3 | |
Recruiting |
NCT06228677 -
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
|
||
Recruiting |
NCT04213963 -
Prospective Study on Primary Aldosteronism in Resistant Hypertension
|
||
Recruiting |
NCT05563077 -
Aerobic Exercise and Resistant Hypertension
|
N/A | |
Recruiting |
NCT03758196 -
Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH)
|
N/A | |
Active, not recruiting |
NCT03179800 -
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
|
N/A | |
Completed |
NCT04519658 -
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
|
Phase 2 | |
Not yet recruiting |
NCT05552300 -
Superselective Adrenal Arterial Embolization for Resistant Hypertension
|
N/A | |
Not yet recruiting |
NCT05426707 -
Remote Ischemic Conditioning for the Treatment of Resistant Hypertension
|
N/A | |
Completed |
NCT04345198 -
Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension
|
N/A | |
Recruiting |
NCT05562934 -
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
|
Phase 2 | |
Recruiting |
NCT06034743 -
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
|
Phase 3 | |
Withdrawn |
NCT02926495 -
Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.
|
N/A | |
Active, not recruiting |
NCT02670681 -
Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects
|
N/A | |
Completed |
NCT02572024 -
The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)
|
N/A | |
Terminated |
NCT02295683 -
Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
|
||
Completed |
NCT02001350 -
Carotid Ultrasound Study
|
N/A | |
Recruiting |
NCT04331691 -
Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension
|
Phase 4 |